Jessica Blackburn received St. Baldrick's Foundation for Pediatric Cancer Research, "Protein tyrosine phosphatases as novel drugs targets in Acute Lymphoblastic Leukemia" $100,000. 6/1/17-5/30/18. This goal of this research is to use zebrafish screens and human leukemia cells to identify FDA-approved
tyrosine phosphatase inhibitors that can be repurposed as targeted anti-cancer therapy in pediatric leukemia.
Jessica Blackburn received NCI Supplement, "Development of fusion oncoprotein models in zebrafish", $163,000. 8/1/17-11/30/18. In response to the Cancer Moonshot Initiative, and in collaboration with St. Jude Children's Research Hospital, this project will use CRISPR technology to develop the first zebrafish models of translocations common to pediatric cancers, with the goal of developing new high- throughput, in vivo drug screening tools.
Jessica Blackburn received NIH New Innovator Award, "Harnessing single cell technology to define self- renewal of normal and malignant stem cells" $2.3 million, 9/1/17-8/30/22. This project utilizes zebrafish leukemia models for single cell sequencing and high resolution in vivo imaging to define the unique biological properties of cancer stem cells, to understand how they respond to chemotherapy in vivo, and to identify new ways to target them therapeutically to prevent leukemia relapse.
Jessica Blackburn recieved the NIH New Innovator Award.
Trevor Creamer received a COBRE Pilot Award entitled “Interplay between calcineurin, Rcan1, and tau in Alzheimer’s disease”, $100,000, 5/1/2017-4/30/2018. In this project we are investigating tau undergoing liquid-liquid phase separation, how that is affected by phosphorylation state and dephosphorylation by calcineurin, and the role of Rcan1 in modulating these processes.
Trevor Creamer received a VPR Research Support Grant entitled “Inhibition of calcineurin by Rcan1 and hyperphosphorylation of tau in Alzheimer’s disease”, $10,000, 7/1/2017-6/30/2017. The goal of this project is to determine the extent to which Rcan1 inhibits calcineurin’s dephosphorylation of tau and how that contributes to neurofibrillary tangle formation in Alzheimer’s disease.
Sidney Whiteheart renewed his RO1 grant entitled “Molecular Mechanism of Platelet exocytosis”. The amount of funding is $1,881,250, with a grant period from 2017-2021.
Sidney Whiteheart received a new VA Merit award entitled “Targeting Platelet Endocytosis and Exocytosis to Control Thrombosis”. The amount of funding is $928,269 and the grant runs from 2017- 2021.
Sidney Whiteheart received a new RO1 entitled “Platelet endocytosis to innate immunity”. The amount of funding is $2,044,892 and the grant runs from 2017-2021.
Sidney Whiteheart received the COBRE pilot award.